全文获取类型
收费全文 | 730篇 |
免费 | 48篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 17篇 |
基础医学 | 113篇 |
口腔科学 | 25篇 |
临床医学 | 63篇 |
内科学 | 192篇 |
皮肤病学 | 10篇 |
神经病学 | 104篇 |
特种医学 | 7篇 |
外科学 | 80篇 |
综合类 | 4篇 |
预防医学 | 30篇 |
眼科学 | 4篇 |
药学 | 67篇 |
中国医学 | 1篇 |
肿瘤学 | 51篇 |
出版年
2023年 | 17篇 |
2022年 | 16篇 |
2021年 | 39篇 |
2020年 | 18篇 |
2019年 | 19篇 |
2018年 | 18篇 |
2017年 | 15篇 |
2016年 | 24篇 |
2015年 | 24篇 |
2014年 | 39篇 |
2013年 | 33篇 |
2012年 | 60篇 |
2011年 | 55篇 |
2010年 | 32篇 |
2009年 | 25篇 |
2008年 | 40篇 |
2007年 | 33篇 |
2006年 | 36篇 |
2005年 | 35篇 |
2004年 | 29篇 |
2003年 | 31篇 |
2002年 | 34篇 |
2001年 | 19篇 |
2000年 | 9篇 |
1999年 | 8篇 |
1998年 | 8篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1983年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1933年 | 1篇 |
排序方式: 共有783条查询结果,搜索用时 15 毫秒
781.
Lieven Lagae Kerstin Alexandra Klotz András Fogarasi Florin Floricel Christoph Reichel Jan-Peer Elshoff Sofia Fleyshman Harriet Kang 《Epilepsia》2023,64(11):2934-2946
Objective
This study was undertaken to evaluate the long-term safety, tolerability, and efficacy of adjunctive brivaracetam (BRV) treatment in pediatric patients with epilepsy.Methods
A phase 3, open-label, multicenter, long-term follow-up trial (N01266; NCT01364597) was conducted on patients (aged 1 month to <17 years at core trial entry; direct enrollers aged 4 to <17 years) treated with BRV. Outcomes included treatment-emergent adverse events (TEAEs), behavior assessments (Achenbach Child Behavior Checklist [CBCL], Behavior Rating Inventory of Executive Function [BRIEF]/BRIEF-Preschool version [BRIEF-P]), and efficacy outcomes (percent change in focal seizure frequency, 50% responder rate for all seizure types for patient subgroups <2 years and ≥2 years of age using daily record card data).Results
Of 257 patients with ≥1 dose of BRV (141 [54.9%] male; mean age = 8.0 years [SD = 4.5]), 36 patients were <2 years of age, and 72.0% of patients had a history of focal seizures. Mean BRV exposure was 3.2 patient-years. At least one TEAE occurred in 93.4% patients, and 32.3% had serious TEAEs. Seven patients died during the trial; no deaths were considered treatment-related. Patients ≥2 years of age had a median decrease in 28-day adjusted focal seizure frequency of 62.9%, and 50.9% had a ≥50% response in all seizures. Patients <2 years of age had a median decrease in 28-day adjusted focal seizure frequency of 96.9%, and 68.2% had a ≥50% response in all seizures. Kaplan–Meier estimated treatment retention was 72.7%, 64.5%, 57.8%, 53.3%, 50.1%, and 44.8% at 1, 2, 3, 4, 5, and 6 years, respectively. Mean changes (baseline to last evaluation) for all Achenbach CBCL and BRIEF-P/BRIEF subscale scores were negative, reflecting stability/slight improvement.Significance
Long-term adjunctive BRV treatment was generally well tolerated and efficacious in reducing seizure frequency, and had high retention rates, with generally stable cognitive/behavioral scores in pediatric patients with epilepsy. 相似文献782.
783.
Thiemo Florin Dinger Jonas Peschke Mehdi Chihi Meltem Gümüs Maryam Said Alejandro Nicolas Santos Jan Rodemerk Anna Michel Marvin Darkwah Oppong Yan Li Cornelius Deuschl Karsten Henning Wrede Philipp René Dammann Benedikt Frank Christoph Kleinschnitz Michael Forsting Ulrich Sure Ramazan Jabbarli 《European journal of neurology》2023,30(2):389-398